AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with "sector leading replacement power".
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings trajectory as the drugmaker prioritises revenue growth through escalating research spending. The broker warns the current valuation looks full at 20 times forecast 2026 earnings despite confidence the company can exceed its $80 billion 2030 revenue target.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at Citi following full-year results and 2026 guidance that the bank described as “reassuring”, with a reiterated target price of £170 and unchanged earnings forecasts. Management confirmed expectations for low double-digit earnings growth in 2026, aligning with consensus, while the medium single- to high single-digit revenue outlook was ahead of market forecasts.
AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
AstraZeneca PLC delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. AZN targets $80bn in revenues by 2030, driven by oncology, pipeline launches, and a $50bn US investment; management expresses increasing confidence. Patent expirations loom for key drugs, but pipeline assets and AI-driven innovation are expected to offset risks and sustain growth.
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AstraZeneca's growth engine stays on track despite cost pressures
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to long-term growth, analysts said. Fourth-quarter revenue came in at $15.5 billion, 2% ahead at constant exchange rates and just over 1% above consensus.
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance across all major regions and sustained pipeline momentum, as the Anglo-Swedish pharmaceutical group continued what it called a “catalyst-rich period.” Total revenue for the year rose 8% at constant exchange rates to $58.7 billion, with product sales contributing $55.6 billion, up 9%.
AstraZeneca profit climbs on cancer and heart drug demand
The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.
